The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells

被引:25
作者
Krupski, T
Harding, MA
Herce, ME
Gulding, KM
Stoler, MH
Theodorescu, D [1 ]
机构
[1] Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22903 USA
[2] Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22903 USA
[3] Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22903 USA
关键词
angiogenesis; vascular endothelial growth factor; prostate neoplasms;
D O I
10.3109/08977190109029117
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Despite the fact that cancer cells can be found in many vascular beds, continued growth of the metastatic tumor focus exhibits a significant degree of "organ tropism", with only certain organs exhibiting the ravages of metastatic disease. Since a limiting factor to the growth of metastases beyond 2 mm in diameter, may be a lack of angiogenesis, we sought to determine whether tumor overexpression of vascular endothelial growth factor (VEGF), a potent angiogenic factor related to prostate cancer metastasis, is causally related to organ specific tumor growth in a prostate cancer xenograft model. LnCaP-C4-2 is a subline of the human prostate cancer cell line LnCaP which unlike its parent, has a predilection for growth in bone, a common site for human prostate cancer metastasis. LnCaP-C4-2, is tumorigenic when injected intrafemorally in mice but requires co-injection of stromal components (Matrigel) to be tumorigenic in the subcutaneous site. Because of this site-specific tumorigenicity profile and relatively low VEGF mRNA and protein expression, this tine was transfected with a full length cDNA encoding the 165 isoform of VEGF. Cells either overexpressing or not expressing the transfected gene were selected for study in vivo and in vitro. Overexpression of VEGF did not seem to affect in vitro cell growth. Such overexpression did affect tumorigenicity and in vivo tumor growth rates when cells were inoculated in the subcutaneus site. Interestingly, the dependency of subcutaneous tumorigenicity on Matrigel co-inoculation was still observed in cells overexpressing VEGF. In contrast to the impact that VEGF overexpression has on subcutaneous tumorigenicity, no such effect was observed when cells were inoculated in orthotopic/prostate (primary) or intrafemoral (metastatic) sites. In view of the importance of tumor-stromal interactions in growth of xenografts, we sought to determine if the host strain is important to the observed tumorigenicity effects of VEGF overexpression. No differences in subcutaneous tumorigenicity as a function of either Matrigel use or VEGF expression levels were observed when SCID/bg and RAG/pfp mouse strains were compared. In conclusion, our data indicate that the biological impact of prostate tumor VEGF overexpression is organ/site specific, leading to the speculation that it may play a part in the observed organ tropism of metastatic spread. In addition, these results highlight the importance of the tumor microenvironment in determining the biological impact of transfected and overexpressed genes in the study of tumor biology.
引用
收藏
页码:287 / +
页数:18
相关论文
共 38 条
[1]  
AUERBACH R, 1988, LAB INVEST, V58, P361
[2]  
Balbay MD, 1999, CLIN CANCER RES, V5, P783
[3]  
Brown T., 1997, CURRENT PROTOCOLS MO
[4]   Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor [J].
Cheng, SY ;
Huang, HJS ;
Nagane, M ;
Ji, XD ;
Wang, DG ;
Shih, CCY ;
Arap, W ;
Huang, CM ;
Cavenee, WK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8502-8507
[5]  
CHUNG LWK, 1995, CANCER SURV, V23, P33
[6]   Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice [J].
Connolly, JM ;
Rose, DP .
JOURNAL OF UROLOGY, 1998, 160 (03) :932-936
[7]   MODULATION OF THE INVASIVE PHENOTYPE OF HUMAN COLON-CARCINOMA CELLS BY ORGAN SPECIFIC FIBROBLASTS OF NUDE-MICE [J].
FABRA, A ;
NAKAJIMA, M ;
BUCANA, CD ;
FIDLER, IJ .
DIFFERENTIATION, 1992, 52 (01) :101-110
[8]  
FIDLER IJ, 1995, AM SURGEON, V61, P1065
[9]  
Folkman J, 1997, EXS, V79, P1
[10]  
Fort MM, 1998, J IMMUNOL, V161, P3256